Mirum Pharmaceuticals, Inc. (MIRM) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
Mirum Pharmaceuticals, Inc. (MIRM) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$222.79 MLiabilities$1.06 BNon-current liabilities$832.62 MCurrent assets$636.31 MAssets$1.04 BNon-current assets$408.67 MEquity−$10.42 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSCash and cash equivalentsAccounts receivableShort-term investmentsPrepaid expenses and other current assetsInventoryIntangible assets, netLong-term investmentsOther assetsOperating lease right-of-use assetsProperty and equipment, netRestricted cashAccrued expenses and other current liabilitiesHoldback liabilities, currentAccounts payableConvertible notes payable, net, noncurrentHoldback liabilities, noncurrentOther liabilitiesOperating lease liabilities, noncurrentAdditional paid-in capitalCommon stock, $0.0001 par value; 200,000,000 shares authorized; 64,754,699 and 51,896,391 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyAccumulated deficitAccumulated other comprehensive (loss) incomeCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityCurrent liabilitiesCurrent liabilities$222.79 MAccrued expenses and other current liabilitiesAccrued expenses and other current liabilities$174.56 MLiabilitiesLiabilities$1.06 BHoldback liabilities, currentHoldback liabilities, current$24.80 MAccounts payableAccounts payable$23.43 MNon-current liabilitiesNon-current liabilities$832.62 MConvertible notes payable, net, noncurrentConvertible notes payable, net, noncurrent$750.08 MHoldback liabilities, noncurrentHoldback liabilities, noncurrent$61.15 MOther liabilitiesOther liabilities$10.92 MCurrent assetsCurrent assets$636.31 MCash and cash equivalentsCash and cash equivalents$330.73 MOperating lease liabilities, noncurrentOperating lease liabilities, noncurrent$10.47 MAccounts receivableAccounts receivable$145.36 MAssetsAssets$1.04 BShort-term investmentsShort-term investments$107.56 MPrepaid expenses and other current assetsPrepaid expenses and other current assets$26.89 MInventoryInventory$25.77 MAdditional paid-in capitalAdditional paid-in capital$1.52 BIntangible assets, netIntangible assets, net$247.39 MNon-current assetsNon-current assets$408.67 MLong-term investmentsLong-term investments$123.03 MOther assetsOther assets$22.24 MOperating lease right-of-use assetsOperating lease right-of-use assets$12.02 MEquityEquity−$10.42 MProperty and equipment, netProperty and equipment, net$2.25 MCommon stock, $0.0001 par value; 200,000,000 shares authorized; 64,754,699 and 51,896,391 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCommon stock$6.00 KRestricted cashRestricted cash$1.73 MAccumulated deficitAccumulated deficit−$1.52 BAccumulated other comprehensive (loss) incomeAccumulated other comprehensive (loss) income−$674.00 K
Chart details

Mirum Pharmaceuticals, Inc. (MIRM) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
1,044,981,000 US dollars
Current assets
636,310,000 US dollars
Non-current assets
408,671,000 US dollars
Liabilities
1,055,403,000 US dollars
Current liabilities
222,788,000 US dollars
Non-current liabilities
832,615,000 US dollars
Equity
negative 10,422,000 US dollars
Cash and cash equivalents
330,728,000 US dollars
Accounts receivable
145,360,000 US dollars
Short-term investments
107,563,000 US dollars
Prepaid expenses and other current assets
26,890,000 US dollars
Inventory
25,769,000 US dollars
Intangible assets, net
247,388,000 US dollars
Long-term investments
123,030,000 US dollars
Other assets
22,244,000 US dollars
Operating lease right-of-use assets
12,024,000 US dollars
Property and equipment, net
2,251,000 US dollars
Restricted cash
1,734,000 US dollars
Accrued expenses and other current liabilities
174,561,000 US dollars
Holdback liabilities, current
24,800,000 US dollars
Accounts payable
23,427,000 US dollars
Convertible notes payable, net, noncurrent
750,079,000 US dollars
Holdback liabilities, noncurrent
61,154,000 US dollars
Other liabilities
10,917,000 US dollars
Operating lease liabilities, noncurrent
10,465,000 US dollars
Additional paid-in capital
1,515,172,000 US dollars
Common stock, $0.0001 par value; 200,000,000 shares authorized; 64,754,699 and 51,896,391 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
6,000 US dollars
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of June 30, 2026 and December 31, 2025
0 US dollars
Accumulated deficit
negative 1,524,926,000 US dollars
Accumulated other comprehensive (loss) income
negative 674,000 US dollars

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
Mirum Pharmaceuticals, Inc. (MIRM) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!